Skip to main content
. Author manuscript; available in PMC: 2022 Sep 15.
Published in final edited form as: Lancet Respir Med. 2020 Aug 4;8(12):1219–1232. doi: 10.1016/S2213-2600(20)30321-0

Figure 1: Histopathological features of lung biopsies submitted for the evaluation of EVALI.

Figure 1:

Lung biopsies submitted to the CDC were characterised on the basis of patterns of acute lung injury on haematoxylin and eosin stained slides. (A) Case 3 showed features of exudative and proliferative diffuse alveolar damage, with prominent hyaline membranes (arrow; 10× magnification). (B) Clusters of foamy macrophages (asterisk) were present in all ten biopsy lung samples and were abundant in case 5 (shown); type II pneumocyte hyperplasia was also prominent in case 5 (arrow; 40× magnification). (C) Features of proliferative and organising diffuse alveolar damage were seen in case 10, including type II pneumocyte hyperplasia (arrow) and fibroblastic proliferations (asterisk; 10× magnification). (D) Fibroblastic proliferations within airways and alveoli (asterisks), consistent with organising pneumonia, were a notable feature in case 7 (10× magnification). (E) Airway-centred inflammation and intrabronchiolar fibroblastic plugs (asterisks), consistent with organising pneumonia, were seen in case (4·5× magnification). (F) Higher magnification of figure 1E (case 4) showing fibroblastic plugs infiltrated by eosinophils and macrophages (40× magnification). CDC=Centers for Disease Control and Prevention. EVALI=e-cigarette, or vaping, product use-associated lung injury.